ONC-392,Pembrolizumab
biontech,Merck
['lung', '$bntx', '$ibb', '$xbi', 'biontech']
$bntx biontech and oncoc4 report promising results for their antibody candidate bnt-316/onc-392 in phase 1/2 clinical trials for hard-to-treat non-small cell lung cancer at asco. more info: $xbi $ibb $xph $pph 
BioPharma/Biotech Intel.  Daily $XBI $XPH Market Movers

Database: https://t.co/IBOqbSoYuc
Clinical trial tools: https://t.co/A77u9Q84Dc  http://globalclinicalt